| Enhanced p53 gene transfer to human ovarian cancer cells using the cationic nonviral vector, DDC. | |
| | |
MedLine Citation:
|
PMID: 12893186 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Previously we have formulated a new cationic liposome, DDC, composed of dioleoyltrimethylamino propane (DOTAP), 1,2-dioeoyl-3-phosphophatidylethanolamine (DOPE), and cholesterol (Chol), and it efficiently delivered plasmid DNA into ovarian cancer cells. Mutations in the p53 tumor suppressor gene are the most common molecular genetic abnormalities to be described in ovarian cancer. However, there has been so far no report of nonviral vector-mediated p53 gene deliveries in ovarian cancer. In this study, wild-type p53 DNA was transfected into the ovarian cancer cells, using the DDC as a nonviral vector and the expression and activity of p53 gene were evaluated both in vitro and in vivo. METHOD: DDC liposomes were prepared by mixing DOTAP:DOPE:Chol in a 1:0.7:0.3 molar ratio using the extrusion method. Plasmid DNA (pp53-EGFP) and DDC complexes were transfected into ovarian carcinoma cells (OVCAR-3 cells) and gene expression was determined by reverse transcription-polymerase chain reaction and Western blot analysis. The cellular growth inhibition and apoptosis of DDC-mediated p53 transfection were assessed by trypan blue exclusion assay and annexin-V staining, respectively. The OVCAR-3 cells treated with DDC/pp53-EGFP complexes were inoculated into female balb/c nude mice and tumor growth was observed. RESULTS: The transfection of liposome-complexed p53 gene resulted in a high level of wild-type p53 mRNA and protein expressions in OVCAR-3 cells. In vitro cell growth assay showed growth inhibition of cancer cells transfected with DDC/pp53-EGFP complexes compared with the control cells. The reestablishment of wild-type p53 function in ovarian cancer cells restored the apoptotic pathway. Following the inoculation of DDC/pp53-EGFP complexes, the volumes of tumors in nude mice were significantly reduced more than 60% compared to the control group. CONCLUSION: The DDC-mediated p53 DNA delivery may have the potential for clinical application as nonviral vector-mediated ovarian cancer therapy due to its effective induction of apoptosis and tumor growth inhibition. |
| | |
Authors:
|
Chong-Kook Kim; Eun-Jeong Choi; Sung-Hee Choi; Jeong-Sook Park; Khawaja Hasnain Haider; Woong Shick Ahn |
Related Documents
:
|
7549756 - High prevalence of expression of p53 oncoprotein in oral carcinomas from india associat... 10820956 - Expression of p53 protein in oral submucous fibrosis, oral epithelial hyperkeratosis, a... 7911636 - Ki-67 and p53 expression in cutaneous bowen's disease: an immunohistochemical study of ... 1357956 - P53 and c-erbb-2 protein expression in breast carcinomas. an immunohistochemical study ... 18575756 - Aberrant methylation of cxcl12 in non-small cell lung cancer is associated with an unfa... 21455986 - β-catenin as a potential key target for tumor suppression. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Gynecologic oncology Volume: 90 ISSN: 0090-8258 ISO Abbreviation: Gynecol. Oncol. Publication Date: 2003 Aug |
Date Detail:
|
Created Date: 2003-08-01 Completed Date: 2003-09-02 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0365304 Medline TA: Gynecol Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 265-72 Citation Subset: IM |
Affiliation:
|
College of Pharmacy, Seoul National University, San 56-1, Shinlim-Dong, Kwanak-Gu, Seoul 151-742, South Korea. ckkim@plaza.snu.ac.kr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
genetics*,
metabolism,
pathology,
therapy Apoptosis / genetics Cell Division / genetics Cholesterol / administration & dosage Fatty Acids, Monounsaturated / administration & dosage Female Genes, p53 / genetics* Genetic Vectors Humans Liposomes / administration & dosage Ovarian Neoplasms / genetics*, metabolism, pathology, therapy Phosphatidylethanolamines / administration & dosage Plasmids / administration & dosage, genetics Quaternary Ammonium Compounds / administration & dosage Transfection / methods* Tumor Cells, Cultured Tumor Suppressor Protein p53 / biosynthesis, genetics |
| Chemical | |
Reg. No./Substance:
|
0/1,2-dioleoyl-glycero-3-phosphatidyl ethanolamine; 0/Fatty Acids, Monounsaturated; 0/Liposomes; 0/Phosphatidylethanolamines; 0/Quaternary Ammonium Compounds; 0/Tumor Suppressor Protein p53; 113669-21-9/1,2-dioleoyloxy-3-(trimethylammonium)propane; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The detection of stage I ovarian cancer by three-dimensional sonography and power Doppler.
Next Document: Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients.